MedPath

Clinical Outcomes of Cyclosporine Eye Drops in Management of Herpetic Keratitis

Phase 4
Completed
Conditions
Outcomes of Cyclosporine Eye Drops in Herpetic Keratitis
Interventions
Registration Number
NCT05720715
Lead Sponsor
Farwaniya Hospital
Brief Summary

Objective: To compare the additive effect of topical cyclosporine A 0.05% eye drops to prednisolone eye drops, with topical prednisolone acetate 1% eye drops alone in treatment of herpetic stromal keratitis.

Methods: Patients diagnosed with herpetic stromal keratitis are randomly divided into 2 groups; Group A: receive cyclosporine eye drops together with prednisolone eye drops.

Group B: receive topical prednisolone with placebo eye drops (tear replacement).

The 2 groups receive systemic acyclovir therapeutic dose 400 mg five times daily, which then tapered to twice daily prophylactic dose after one month of treatment. Follow up for patients is scheduled as a weekly visit for a duration of 2 months.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Patients diagnosed with herpetic stromal keratitis
Exclusion Criteria
  • associated ocular diseases, DM, renal disease, pregnancy, breast feeding.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
group Acyclosporine A 0.05% eye dropsreceive cyclosporine eye drops together with prednisolone eye drops.
group Bcyclosporine A 0.05% eye dropsreceive topical prednisolone with placebo eye drops (tear replacement).
Primary Outcome Measures
NameTimeMethod
duration of ttt3 months

duration of treatment until complete resolving of keratitis

Secondary Outcome Measures
NameTimeMethod
improvement in visual acuity3 months

by snellen chart

Trial Locations

Locations (1)

Farwanyia Hospital

🇰🇼

Al Farwānīyah, Farwanyia, Kuwait

© Copyright 2025. All Rights Reserved by MedPath